Abris Heisz
Research Subjects
Abris Heisz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Minguela
Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain
1 shared publication - Andras Szasz
VERDI Solutions GmbH, 1070 Vienna, Austria
1 shared publication Bartolome Garcia Perez
Hospital Clínico Universitario Virgen de la Arrixaca and Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain
1 shared publication- Carlos Manuel Martínez
Department of Anatomy and Comparative Pathology, Faculty of Veterinary Science, University of Murcia, Campus de Espinardo, 30100 Murcia, Spain
1 shared publication - Franco Lori
ViroStatics srl, Viale Umberto I, 46, 07100 Sassari, Italy
1 shared publication - Jose Maria Moraleda
ATMPs Production Unit-GMP Facility, Biomedical Research Institute of Murcia Pascual Parrilla—IMIB, Virgen de la Arrixaca University Clinical Hospital, 30120 Murcia, Spain
1 shared publication
Latest Publications
- Open Access
- 13 October 2025
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003221
Personalized peptide vaccines induce predicted T cell responses against signet ring cell carcinoma—a case report
T cell-based immunotherapies increasingly include personalized neoantigen vaccines that target tumor-specific mutations. However, despite their promise, current neoantigen vaccines show limited and unpredictable clinical benefit, with T cell responses observed in only a subset of patients. To overcome these limitations, we developed the VERDI (Vaccine Epitopes Ranked by Digital Intelligence) System—a cloud-based computational platform that integrates a patient’s human leukocyte antigen (HLA) class I and II genotype with selected tumor-associated antigens (TAAs), including cancer-testis antigens (CTAs), to identify peptides with high predicted immunogenicity and low risk of immune-related adverse events (irAEs). Using the VERDI System, we designed ten personalized peptide vaccines for a patient with metastatic signet ring cell carcinoma (SRCC), a rare and aggressive gastric cancer with limited treatment options. All ten VERDI vaccines were well tolerated and consistently induced tumor-specific T cell responses following a single administration, without the need for checkpoint inhibitors. The patient survived for 15 months—substantially longer than the reported median survival of 5.6 months in metastatic SRCC—highlighting the potential of this individualized, predictive vaccine platform to improve outcomes in advanced cancer.
- 13 October 2025
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003221
Open AccessPersonalized peptide vaccines induce predicted T cell responses against signet ring cell carcinoma—a case report
T cell-based immunotherapies increasingly include personalized neoantigen vaccines that target tumor-specific mutations. However, despite their promise, current neoantigen vaccines show limited and unpredictable clinical benefit, with T cell responses observed in only a subset of patients. To overcome these limitations, we developed the VERDI (Vaccine Epitopes Ranked by Digital Intelligence) System—a cloud-based computational platform that integrates a patient’s human leukocyte antigen (HLA) class I and II genotype with selected tumor-associated antigens (TAAs), including cancer-testis antigens (CTAs), to identify peptides with high predicted immunogenicity and low risk of immune-related adverse events (irAEs). Using the VERDI System, we designed ten personalized peptide vaccines for a patient with metastatic signet ring cell carcinoma (SRCC), a rare and aggressive gastric cancer with limited treatment options. All ten VERDI vaccines were well tolerated and consistently induced tumor-specific T cell responses following a single administration, without the need for checkpoint inhibitors. The patient survived for 15 months—substantially longer than the reported median survival of 5.6 months in metastatic SRCC—highlighting the potential of this individualized, predictive vaccine platform to improve outcomes in advanced cancer.